SAO PAULO (Reuters) – Brazilian health authority Anvisa said on Friday it received an application from São Paulo-based medical center Butantan for emergency use in Brazil of a COVID-19 vaccine developed by China’s Sinovac Biotech, according to a statement.
Butantan is Sinovac’s partner and is producing the vaccine locally. Anvisa said in the statement it plans to conclude the evaluation of Butantan’s request for emergency use of the vaccine in up to 10 days.
(Reporting by Lisandra Paraguassu; Writing by Ana Mano; Editing by Chizu Nomiyama)
